The Bell2Bell (B2B) Podcast

Bell2Bell’s latest podcast features Wa’el Hashad, CEO of Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty.

To begin the interview, Hashad introduced Longeveron and its business model.

“Longeveron is a cell therapy-based biotech company. It was established in 2014 as a spin-off from a technology that was developed at the University of Miami School of Medicine by a renowned scientist and cardiologist, Dr. Josh Hare,” Hashad said. “Josh has been working since he graduated medical school… on trying to help patients regenerate their heart muscles after heart attacks. He continued to use stem cells – specifically mesenchymal stem cells, or medicinal signaling cells – to try to develop medicines that may help patients have a better outcome after heart attacks and so on.”